Gilead's $5B Galapagos black hole widens as pair toss out phase 3 asset after flop

Gilead has sunk billions into Galapagos over the past few years, but this is quickly turning into one of the most disastrous biotech deals in recent history.

Today, the once tightly-knit pair came further apart at the seams when an independent body checked out its phase 3 data for the experimental autotaxin inhibitor ziritaxestat in patients with idiopathic pulmonary fibrosis (IPF).